SCTR and pancreatic ductal adenocarcinoma: While it remains poorly studied in CRC, the SCTR has been found overexpressed in gastrinomas [61], bronchopulmonary carcinoid tumors [62] cholangiocarcinoma [61], esophageal, and pancreatic ductal adenocarcinomas [61] and considered a candidate target for molecular tumor imaging as well as for peptide receptor radioligand therapy [63].